MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) announces the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals. scPharmaceuticals currently markets FUROSCIX, an FDA-approved on-body infuser delivering furosemide, the gold standard to treat fluid overload in adult patients with chronic heart failure (CHF) and chronic kidney disease (CKD). Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock for a total deal value of up to approximately $360 million.
Read the full article: MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases //
Source: https://www.globenewswire.com/news-release/2025/08/25/3138371/0/en/MannKind-to-Acquire-scPharmaceuticals-Accelerating-Revenue-Growth-and-Emerging-as-a-Patient-Centric-Leader-in-Cardiometabolic-and-Lung-Diseases.html